Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 37 (5), 1202-19

Nonalcoholic Steatohepatitis: Summary of an AASLD Single Topic Conference


Nonalcoholic Steatohepatitis: Summary of an AASLD Single Topic Conference

Brent A Neuschwander-Tetri et al. Hepatology.

Erratum in

  • Hepatology. 2003 Aug;38(2):536


Fatty liver disease that develops in the absence of alcohol abuse is recognized increasingly as a major health burden. This report summarizes the presentations and discussions at a Single Topic Conference held September 20-22, 2002, and sponsored by the American Association for the Study of Liver Diseases. The conference focused on fatty liver disorders. Estimates based on imaging and autopsy studies suggest that about 20% to 30% of adults in the United States and other Western countries have excess fat accumulation in the liver. About 10% of these individuals, or fully 2% to 3% of adults, are estimated to meet current diagnostic criteria for nonalcoholic steatohepatitis (NASH). Sustained liver injury leads to progressive fibrosis and cirrhosis in a fraction, possibly up to one third, of those with NASH, and NASH may be a cause of cryptogenic cirrhosis. NASH is now a significant health issue for obese children as well, leading to cirrhosis in some. The diagnostic criteria for NASH continue to evolve and rely on the histologic findings of steatosis, hepatocellular injury (ballooning, Mallory bodies), and the pattern of fibrosis. Generally recognized indications for biopsy include establishing the diagnosis and staging of the injury, but strict guidelines do not exist. Liver enzymes are insensitive and cannot be used reliably to confirm the diagnosis or stage the extent of fibrosis. Older age, obesity, and diabetes are predictive of fibrosis. The pathogenesis of NASH is multifactorial. Insulin resistance may be an important factor in the accumulation of hepatocellular fat, whereas excess intracellular fatty acids, oxidant stress, adenosine triphosphate (ATP) depletion, and mitochondrial dysfunction may be important causes of hepatocellular injury in the steatotic liver. Efforts are underway to refine the role of insulin resistance in NASH and determine whether improving insulin sensitivity pharmacologically is an effective treatment. An altered lifestyle may be a more effective means of improving insulin sensitivity. The research agenda for the future includes establishing the role of insulin resistance and abnormal lipoprotein metabolism in NASH, determining the pathogenesis of cellular injury, defining predisposing genetic abnormalities, identifying better noninvasive predictors of disease, and defining effective therapy.

Similar articles

  • [Nonalcoholic Steatohepatitis: Pathogenesis and Treatment]
    SH Park. Korean J Hepatol 14 (1), 12-27. PMID 18367854. - Review
    Nonalcoholic fatty liver disease (NAFLD) is characterized by a wide spectrum of liver damage spanning steatosis, nonalcoholic steatohepatitis (NASH), cryptogenic liver ci …
  • Non-alcoholic Steatohepatitis in Children
    K Nanda. Pediatr Transplant 8 (6), 613-8. PMID 15598336. - Review
    Obesity has emerged as a significant new health problem in the pediatric population. Non-alcoholic steatohepatitis (NASH) is an entity in the spectrum of non-alcoholic fa …
  • Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
    X Ma et al. Chin J Dig Dis 7 (1), 7-11. PMID 16412031. - Review
    Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of liver diseases that range from hepatic steatosis at the most clinically benign end of the spectrum, thro …
  • Hepatic Histopathology of Morbid Obesity: Concurrence of Other Forms of Chronic Liver Disease
    PL Liew et al. Obes Surg 16 (12), 1584-93. PMID 17217634.
    Hepatic steatosis, features of metabolic syndrome and liver cell injuries were common in morbidly obese patients. Abnormal liver function and portal inflammation were rel …
  • [Non-alcoholic Fatty Liver Disease--New View]
    J Raszeja-Wyszomirska et al. Pol Merkur Lekarski 24 (144), 568-71. PMID 18702346. - Review
    Non-alcoholic fatty liver disease (NAFLD) covers a wide spectrum of liver pathology--from steatosis alone, through the necroinflammatory disorder of non-alcoholic steatoh …
See all similar articles

Cited by 528 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources